BACKGROUND The adrenal sex hormone dehydroepiandrosterone (DHEA), which is present in serum mainly as the
T he adrenal sex hormone dehydroepiandrosterone (DHEA) is the most abundant steroid hormone in human blood. It is present in serum mainly as a sulfate ester (DHEA-S) (1, 2) . DHEA may exert biological effects via peripheral conversion into sex steroids, such as testosterone and estradiol, but other DHEA metabolites may also be biologically active. Direct effects of DHEA have been proposed (1) (2) (3) .
DHEA/-S levels decline dramatically with age (4); however, the mechanism behind this decline and its consequences for health are unclear (5) .
DHEA has been hypothesized to be important for body composition, insulin sensitivity, and endothelial function (1, 4, 6) , and DHEA may reduce vascular inflammation and remodeling, platelet aggregation, oxidative stress, and atherosclerosis, which suggests that DHEA may confer vascular protection (1) (2) (3) (6) (7) (8) (9) . Consequently, it has been speculated that relative DHEA/-S deficiency with increasing age may contribute to age-related cardiometabolic disease (4) . However, although there is a relatively large body of published data on the vascular and metabolic actions of DHEA in experimental models, the relevance of these results for human physiology and pathophysiology is uncertain (4) .
Several studies that addressed the association between DHEA/-S levels and cardiovascular disease (CVD) outcomes showed inconsistent findings (6, (10) (11) (12) (13) (14) (15) . In prospective studies, our group and others previously reported an increased risk of both all-cause and CVD mortality among elderly men with the lowest DHEA/-S levels (16) (17) (18) . However, the data regarding DHEA/-S and CVD mortality in men also conflict (19, 20) and may be confounded by DHEA/-S levels that are suppressed in severe illness (21, 22) . One prospective study reported an association between low DHEA/-S and combined fatal and nonfatal coronary heart disease (CHD) events in men only when self-report of treated CHD and CHD medication were included as events in the analysis (23) .
Thus, there is a need for large population-based studies to address the potential association between DHEA/-S and CVD outcomes.
The aim of the present study was to test the hypothesis that serum DHEA and/or DHEA-S levels are predictors of major CHD and/or cerebrovascular disease (CBD) events in a large population-based cohort of elderly men. We used state-of-the-art methodology to assay baseline DHEA and DHEA-S serum levels, and had a complete 5-year follow-up for CHD (including hospitalization for acute myocardial infarction, unstable angina, or revascularization, or death from CHD) and CBD (including hospitalization for stroke or transient ischemic attack, or death from stroke) endpoints.
METHODS STUDY POPULATION. The multicenter MrOS (Osteoporotic Fractures in Men Study) includes older men in
Sweden, Hong Kong, and the United States. Swedish study participants (age 69 to 81 years) were randomly selected from national population registers (24) .
Eligibility required the ability to walk without walking aids, ability to provide self-reported data, and to understand and sign an informed consent; 45% of those contacted participated in the MrOS Study in Sweden (n ¼ 3,014), which included cohorts in 3 cities: Malmö (n ¼ 1,005), Göteborg (n ¼ 1,010), and Uppsala (n ¼ 999). The ethics committees at Göteborg, Lund, and Uppsala Universities approved the study.
We investigated the associations between serum DHEA and DHEA-S with CHD and/or CBD events in the Swedish MrOS cohort. Serum samples were drawn in the morning (before 10 AM; 69% of the cohort) or around noon (between 10 AM and 3 PM, average 1 PM; 31%).
A sufficient amount of serum for assessment of DHEA by gas chromatography-mass spectroscopy was available for 2,639 men (99% of the participants in the Göteborg cohort, 96% in the Malmö cohort, and 68% in the Uppsala cohort). Of these, 223 participants were excluded for the following reasons: treatment with testosterone, 5alpha-reductase inhibitors, gonadotrophin-releasing hormone agonists, or antiandrogens, or the participants had a history of surgical castration. This left 2,416 men for the present analyses.
ASSESSMENT OF COVARIATES. We used a standardized questionnaire (25) to gather information about smoking habits and self-reported medical diagnoses (including hypertension, diabetes, and myocardial infarction). Diabetes was defined as a selfreported medical diagnosis of diabetes. Hypertension was defined as a self-reported medical diagnosis with either self-reported antihypertensive treatment or a supine systolic blood pressure of $140 mm Hg (measured after a 10-min rest). Standard equipment was used to measure height and weight; body mass index (BMI) was calculated as kilograms (weight)/ meters squared (height). 0.15-mm film thickness) with helium as the carrier gas.
The analytes and the internal standard were detected using a HP5973 quadrupole mass spectrometer equipped with a chemical ionization source. DHEA-S (limit of detection, 0.075 mg/ml; intra-assay CV, 5.2%; interassay CV, 6.3%) was analyzed by a validated liquid chromatography-tandem mass spectroscopy method using turbo ion spray, as previously described (27) . To measure the serum sex hormonebinding globulin, we used an immunoradiometric assay (Orion Diagnostics, Espoo, Finland; limit of detection, 1.3 nmol/l; intra-assay CV, 3%; interassay CV, 7%). 
RESULTS
At baseline, the mean age of the cohort (n ¼ 2,614) was 75.4 years ( Table 1) . Serum levels of DHEA and DHEA-S in the cohort were highly collinear (r ¼ 0.73; p < 0.001), but their covariates differed slightly (Tables 2 and 3 ). The covariates of DHEA and DHEA-S levels in a multiple regression model (Table 3) were age, BMI, hsCRP, and diabetes. Together with these factors, DHEA, but not DHEA-S, levels were also highly influenced by the time of blood sampling and renal function.
During follow-up, a total of 302 participants expe- In prospective analyses, DHEA and DHEA-S levels were both inversely associated with the age-adjusted risk of CHD events when analyzed as continuous variables ( Table 4 , Model 1). In contrast, there was no statistically significant association between DHEA or DHEA-S and CBD events in the corresponding analyses ( Table 4) . After adjustment for traditional cardiovascular risk factors (age, BMI, smoking, diabetes, hypertension, and the ApoB/A1 ratio; Model 2), the associations between DHEA/-S and CHD risk remained significant ( Table 4) . Spline and quadratic models did not support a nonlinear association between DHEA level and CHD risk ( Figure 1 , and data not shown).
Because DHEA/-S may modulate immune responses (7), we addressed inflammation as a potential mediator between a lower DHEA/-S level and increased CHD risk. Adjustment of the association for hsCRP level did not materially change the association between DHEA/-S and CHD risk ( Table 4) .
Both DHEA and DHEA-S levels were directly associated with renal function as assessed by eGFR (Table 2) . Therefore, we adjusted the association between DHEA/-S and CHD risk for eGFR and found that Abbreviations as in Table 1 .
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the point estimates for CHD risk did not materially change ( Table 4) .
DHEA/-S is a precursor hormone for testosterone and estradiol (4) . DHEA showed an association with serum testosterone (r ¼ 0.21; p < 0.001) and estradiol (r ¼ 0.14; p < 0.001) that was slightly stronger than the association between DHEA-S and testosterone (r ¼ 0.05; p ¼ 0.010) and estradiol (r ¼ 0.06; p ¼ 0.005), respectively. After the adjustment of the association between low DHEA/-S and CHD risk for serum total testosterone and estradiol, the associations remained unchanged ( Table 4) .
We also examined the association between DHEA/-S and the sex hormone-binding globulin, which has an important role in sex hormone biology (34) . Sex hormone-binding globulin levels were significantly associated with DHEA-S (r ¼ -0.09; p < 0.001), but these levels were not associated with DHEA (r ¼ 0.03; p ¼ 0.095). Adjustment for the sex hormone-binding globulin level did not change the association between DHEA/-S and CHD events ( Table 4) .
In a subanalysis, we examined the associations between DHEA/-S and outcomes across the components of the CHD composite endpoint (Online Table S1 ). We found that the point estimates for the DHEA/-S association with CHD death, hospitalization for myocardial infarction, hospitalization for unstable angina, and hospitalization for revascularization were all in the same direction; the strongest point estimates were for CHD death and hospitalization for unstable angina, and the weakest point estimates were for revascularization procedures.
To illustrate the association between DHEA status and CVD risk, we plotted unadjusted Kaplan-Meier curves of CHD and CBD event-free survival stratified by DHEA tertiles. These plots illustrated that men with relatively lower DHEA levels had a statistically significantly increased risk of a CHD event (Figure 2A ), but did not have an increased risk of a CBD event ( Figure 2B ).
DHEA levels are suppressed in severe illness (21, 22) . Therefore, general health status is a potential confounder of observed associations. To study the role of subclinical diseases, we performed an analysis that excluded men with a short follow-up time, which is indicative of poor health at the baseline examination. After exclusion of men with a follow-up of 2.6 years or less (one-half of the median follow-up time), the age-adjusted association between low DHEA levels and CHD risk was not attenuated (Table 5) . Similarly, the association between DHEA and CHD risk remained following the exclusion of men with reduced renal function (eGFR #45 ml/min/ 1.73 m 2 ) and men without morning samples.
Furthermore, the association between DHEA and CHD risk remained after exclusion of men with a baseline history of myocardial infarction.
DISCUSSION
In the present large, population-based cohort study of elderly men followed for 5 years, we found that baseline serum levels of DHEA and DHEA-S predicted future CHD events (Central Illustration). In contrast, DHEA/-S showed no statistically significant Abbreviations as in Table 1 . CHD ¼ coronary heart disease; CBD ¼ cerebrovascular disease; CI ¼ confidence interval; HR ¼ hazard ratio; other abbreviations as in Table 1 . Previous epidemiological evidence of an association between DHEA/-S levels and CVD outcomes in men are contradictory (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) 23, 35) . A prospective, nested case-control study reported lower DHEA-S levels among fatal CHD cases (10), but several smaller prospective case-control studies of fatal and/or nonfatal CHD events (13) (14) (15) found no association with DHEA-S levels. In larger prospective cohort studies, we and others previously found an increased risk of both all-cause and CVD mortality among elderly men with the lowest DHEA/-S levels (16-18), but other large studies found no association between DHEA-S and CVD mortality in men (19, 20) . In addition, a population-based study reported no association between DHEA-S levels and incident CVD in 2,084 middle-aged men (mean age 55 years) (35) . The Massachusetts Male Aging Study found no significant association between low DHEA/-S levels and 9-year CHD mortality in 1,167 men age 40 to 70 years.
However, this study did find an association between low DHEA/-S levels and combined fatal and nonfatal CHD events (151 events), but only when self-report of treated CHD and CHD medication were included as events in the analysis (23) . Taken together, previous data are conflicting, and there is a paucity of large prospective analyses on this topic. Our study represents the largest study to date (302 men with CHD events and 225 men with CBD events in 2,416 men at risk), and strongly supports an association between DHEA/-S levels and CHD risk in (elderly) men. Although collinear, the covariates of DHEA and DHEA-S differed slightly. In line with previous findings that DHEA secretion follows a diurnal rhythm similar to that of cortisol (2, 16) , DHEA was associated with the time of blood sampling, whereas DHEA-S did not show such an association, as expected from its significantly longer half-life (2). Importantly, DHEA, Per SD increase; Model 1 (from Table 4 Abbreviations as in Tables 1 and 4 . Our study also had notable strengths, including the mass spectrometry DHEA/-S methodology, a large well-characterized sample, complete followup, fatal and nonfatal outcomes, and the documented accuracy of classification in nationwide Swedish registers (30) .
CONCLUSIONS
Low-serum levels of DHEA and its sulfate predicted the risk of CHD, but not the risk of CBD, events in elderly men.
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